U.S., June 19 -- ClinicalTrials.gov registry received information related to the study (NCT07025889) titled 'IBI343 Combined With Sintilimab Plus Chemotherapy in Gastric Cancer' on June 05.
Brief Summary: This is a Single-arm, Open-label, Phase 1b/2 Study of IBI343 Combined with Sintilimab Plus Chemotherapy in Previously Untreated, Claudin (CLDN) 18.2-positive, HER2-negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Study Start Date: June 02
Study Type: INTERVENTIONAL
Condition:
Gastric Cancer
Intervention:
DRUG: IBI343
Subjects in the phase 1b stage will receive IBI343 3/4.5/6mg/kg intravenous infusion (IV) D1 Q3W in 3-week cycles.
Subjects in the phase 2 stage will receive IB...